Equillium (EQ) Cash from Operations Growth (1y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 85.14% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 74.39% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.23% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 158.60% |
| 10 | Equillium | 279.21 Mn | 218.82 Mn | - | 47.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.35% |
| Dec 31, 2025 | 5.03% |
| Sep 30, 2025 | -10.11% |
| Jun 30, 2025 | -512.74% |
| Mar 31, 2025 | 7.17% |
| Dec 31, 2024 | 41.75% |
| Sep 30, 2024 | -301.10% |
| Jun 30, 2024 | 111.75% |
| Mar 31, 2024 | -10.07% |
| Dec 31, 2023 | -120.43% |
| Sep 30, 2023 | 85.39% |
| Jun 30, 2023 | 44.80% |
| Mar 31, 2023 | 34.11% |
| Dec 31, 2022 | 373.61% |
| Sep 30, 2022 | -86.38% |
| Jun 30, 2022 | -60.98% |
| Mar 31, 2022 | -52.74% |
| Dec 31, 2021 | -22.78% |
| Sep 30, 2021 | -42.45% |
| Jun 30, 2021 | -37.68% |
| Mar 31, 2021 | -24.71% |
| Dec 31, 2020 | 8.64% |
| Sep 30, 2020 | -4.79% |
| Jun 30, 2020 | -6.81% |
| Mar 31, 2020 | -42.70% |
| Dec 31, 2019 | -136.10% |
| Sep 30, 2019 | -185.99% |
| Jun 30, 2019 | -306.84% |
| Mar 31, 2019 | -402.14% |